Regnum Corp. (RGMP)
Regnum Corp. operates in the Entertainment industry of the Communication Services sector, headquartered in New York City, NY, US. The stock last traded at $0.00, up 0.00% on the session, giving a market capitalisation of $2,295. On trailing twelve-month figures it carries a trailing P/E of -0.00, a net margin of 0.0%. Its beta of -0.80 implies it has historically moved less than the broad market.
Regnum Corp. develops and commercializes therapeutics that treat rare and infectious diseases. It develops Leronlimab (PRO 140), a monoclonal antibody CC chemokine receptor type 5 antagonist, that is designed to prevent human immunodeficiency virus from entering human cells. The company was incorporated in 2016 and is based in New York, New York.
Regnum Corp. is most often compared with the following Communication Services names: